For Vaccines

Owing to the serious and far-reaching impacts of emerging diseases like COVID-19, Dengue, Zika, and Ebola and the resurgence of old diseases like measles, malaria, and tuberculosis, vaccine development has become one of the most critical and rapidly accelerating areas in pharmaceuticals and biotechnology. The importance of vaccines in public health on a global scale is now firmly established and subject to much attention from society and the science fraternity as a variety of new-generation vaccines are being researched and developed, especially for new and persisting diseases with no known cure.

The recent significant advances in vaccine technology have necessitated the formulation of new regulations to ensure their efficacy and safety. ImmunitasBio has developed a portfolio of assays, from basic to highly advanced, that can be tailor-made/customized to specific requirements. Our vast expertise in immunology, along with capabilities across a wide range of technologies, enables the swift and successful development of your vaccine products in accordance with the latest regulatory requirements, both global and regional.

Here we highlight some of the assays routinely performed:
Enumeration of antigen-specific functional T-cells in PBMCs by ELISpot
AIM assay to phenotype CD4 and CD8 T-cells by Flow Cytometry
Enumeration of antigen-specific antibody-secreting B-cells by ELISpot
Enumeration of antigen-specific memory B-cells by ELISpot
Th1 vs Th2 phenotyping of vaccine-induced immune response by ELISpot/Luminex